Syngeneic cancer cells with humanized targets for immunotherapy drug development

Combine with Humanized Target humanized GEMM Models to Assess Human Ligand-Receptor Interaction

The preclinical development of human-specific immunotherapeutics such as checkpoint inhibitors is currently hampered by a lack of immunotherapy models featuring human targets in the presence of a functional immune system.

We’ve developed mouse tumor cells engineered to express humanized targets such as PD-L1. You can use these models to evaluate the efficacy of human specific agents targeting humanized proteins expressed on tumor cells.

When combined with humanized GEMM models provides an ideal platform for assessing human specific agents targeting the immune system.

Available Models

Choose the model that fits your research needs.

These models are fully validated for human protein expression by FACS, as well as ligand and antibody binding.

Benefits of humanized syngeneic models

• Save study resources by using combined models as a cost effective alternative to more complex fully humanized models.
• Evaluate human-specific biological therapies in vivo when no mouse ortholog is available.
• Assess human ligand-receptor interaction.